- Agilent to Participate in Jefferies Global Healthcare Conference
May 11, 2026
SANTA CLARA, Calif., May 11, 2026--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 9:20 EDT on Wednesday, June 3, 2026, in New York City. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260511375185/en/
Contacts
INVESTOR CONTACT:
Tejas Savant
+1 917-574-4018
tejas.savant@agilent.com
MEDIA CONTACT:
Kate Coyle
+1 302-633-7490
kate.coyle@agilent.com
View Comments
- Agilent to Participate in Jefferies Global Healthcare Conference
May 11, 2026 · businesswire.com
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 9:20 EDT on Wednesday, June 3, 2026, in New York City. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global lead.
- AGILENT TO PARTICIPATE IN JEFFERIES GLOBAL HEALTHCARE CONFERENCE
May 11, 2026
SANTA CLARA, CALIF.--(BUSINESS WIRE)--AGILENT TECHNOLOGIES INC. (NYSE: A) TODAY ANNOUNCED THAT CEO PADRAIG MCDONNELL AND CFO ADAM ELINOFF WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE. THE EVENT IS SCHEDULED FOR 9:20 EDT ON WEDNESDAY, JUNE 3, 2026, IN NEW YORK CITY. A LIVE AUDIO WEBCAST AND REPLAY OF THE PRESENTATION WILL BE AVAILABLE THROUGH AGILENT'S INVESTOR RELATIONS WEBSITE. ABOUT AGILENT TECHNOLOGIES AGILENT TECHNOLOGIES, INC. (NYSE: A) IS A GLOBAL LEAD.
- Agilent Taps Cirena To Turn Long RNA Technology Into Genome Editing Growth
May 10, 2026
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Agilent Technologies (NYSE:A) has licensed its long RNA purification technology to Cirena for genome editing applications. The agreement focuses on scalable production of high purity long RNA constructs for use in CRISPR and functional genomics workflows. The development expands Agilent's presence in synthetic RNA tools beyond its existing diagnostics and measurement offerings.
Agilent Technologies, trading on the NYSE as NYSE:A, is extending its reach in biotech tools with this licensing move, while its shares most recently closed at $118.65. Over the past week the stock is up 2.7%, and over the past month it is up 4.2%, with a 10.0% gain over the past year. These returns place the Cirena agreement within a broader effort to remain active in high growth research workflows.
For investors, the focus now is on how this long RNA purification technology is adopted and where it fits in next generation therapeutics and research pipelines. The Cirena partnership gives Agilent a foothold in synthetic RNA production that may influence future collaborations, product offerings, and revenue mix without changing the company’s core role in diagnostics and measurement solutions.
Stay updated on the most important news stories for Agilent Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Agilent Technologies.NYSE:A Earnings & Revenue Growth as at May 2026
4 things going right for Agilent Technologies that this headline doesn't cover.
The Cirena licensing agreement plugs Agilent’s long RNA purification technology directly into genome editing workflows, which sit alongside tools sold by peers such as Thermo Fisher Scientific, Danaher and Illumina. Instead of building a full RNA production business, Agilent is supplying a process that targets a bottleneck in long RNA purity, while Cirena handles synthesis and scale up. For you as an investor, this keeps Agilent closer to its core of measurement, sample prep and workflow software, while still giving it exposure to CRISPR and functional genomics demand. Because it is a licensing arrangement, the economics are likely tied to Cirena’s volume and customer uptake rather than large upfront spending by Agilent, which can matter for capital discipline and risk. The deal also follows regulatory wins such as PD L1 companion diagnostics approvals, suggesting management is trying to position the portfolio across both translational research and clinical decision tools.
Story Continues
How This Fits Into The Agilent Technologies Narrative
The deal lines up with the narrative focus on next generation lab technologies and recurring revenue, because long RNA purification can support repeat demand in CRISPR and functional genomics workflows. If tariff driven costs or funding pressures tighten budgets at research customers, adoption for higher priced long RNA workflows could be slower than the narrative’s growth assumptions imply. The licensing economics, and any follow on agreements with other RNA or gene editing players, may not be fully captured in the current narrative, which centers more on instruments, diagnostics and services.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Agilent Technologies to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
⚠️ Execution risk if Cirena struggles to scale production or win customers in a field where established tool providers already have relationships with major labs. ⚠️ Dependence on research and biotech funding cycles, which can affect demand for advanced CRISPR and long RNA tools if budgets tighten in academia or early stage biotech. 🎁 Added exposure to genome editing workflows through a licensing structure, which can broaden Agilent’s role in RNA based research without large manufacturing build outs. 🎁 Alignment with four identified rewards, including past and forecast earnings growth and trading below some fair value estimates, which some investors may see as supportive if the RNA opportunity develops well over time.
What To Watch Going Forward
From here, focus on signs that Cirena is integrating Agilent’s technology into products that gain traction, such as customer case studies, new CRISPR workflow kits or references in genome editing collaborations. It is also worth tracking how often management talks about synthetic RNA tools alongside diagnostics approvals and software in future updates, because that can show whether RNA workflows are becoming a more meaningful part of the story. Is Agilent Technologies's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Agilent Technologies, head to the community page for Agilent Technologies to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include A.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Mettler-Toledo Q1 Earnings Top Estimates, Sales Increase Y/Y
May 8, 2026
Mettler-Toledo International MTD delivered first-quarter 2026 adjusted earnings of $8.91 per share, beating the Zacks Consensus by 2.44%. The bottom line increased 8.8% on a year-over-year basis.
Net sales were $947.1 million, up 7% year over year (up 3% in local currency), beating the Zacks Consensus Estimate by 0.04%.
MTD Navigates a More Uneven Regional Backdrop
On a local-currency basis, MTD’s sales increased 2% in the Americas, 1% in Europe, and 5% in Asia/Rest of World in the quarter. Excluding acquisitions, local-currency sales increased 1%, including flat performance in the Americas and 3% growth in Asia/Rest of World.
Americas sales rose to $389 million from $378 million, representing 41% of total revenues, Europe sales increased to $279 million from $248 million, representing 29% of total revenue, and Asia/Rest of World sales rose to $279 million from $258 million, which accounted for 29% of total revenues.
Mettler-Toledo International, Inc. Price, Consensus and EPS SurpriseMettler-Toledo International, Inc. Price, Consensus and EPS Surprise
Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Toledo International, Inc. Quote
Mettler-Toledo Sees Mixed Growth Across Product Lines
By product category, Mettler-Toledo’s Laboratory business generated $525 million of sales in the first quarter compared with $500 million a year ago. Industrial sales rose to $375 million from $341 million, while Food Retail increased to $48 million from $42 million, taking total segment sales to $947 million from $884 million.
On a local-currency basis, Laboratory was up 1%, Industrial up 5%, and Food Retail up 7%, with total reported down 3% in that specific local-currency view. The company also noted that local-currency growth excluding acquisitions was 1%, including flat sales growth in Laboratory and 2% in Industrial for the three months ended March 31, 2026.
Mettler-Toledo’s Q1 Operating Details
Gross profit was $555.8 million, implying a gross margin of 58.7% compared with 59.5% in the year-ago period, a decline of 80 basis points.
Operating expense lines showed measured growth. Research and development expense was $51.3 million, up 10.6% year over year. Selling, general, and administrative expenses were $258.3 million, up 6.4% year over year.
Adjusted operating profit increased 4% year over year to $246.2 million. The adjusted operating margin was 26%, which declined 80 bps year over year.
MTD’s Balance Sheet & Cash Flow
As of March 31, 2026, Mettler-Toledo’s cash and cash-equivalent balance was $60.5 million, down from $66.9 million as of Dec. 31, 2025. The long-term debt was $2.16 billion as of March 31, 2026.
Cash flow from operating activities totaled $139.8 million in the quarter, while adjusted free cash flow was $119.7 million.
On capital allocation, the company repurchased $206.3 million of common stock during the period.
Story Continues
Mettler-Toledo’s Q2 & FY26 Guidance
Management cautioned that market conditions remain uncertain and “could change quickly,” but guided for second-quarter 2026 local-currency sales growth of approximately 3%. Adjusted earnings for the second quarter are forecasted to be in the range of $10.70 to $10.85 per share, implying 6% to 8% growth year over year.
For 2026, MTD reaffirmed expected local-currency sales growth of approximately 4% and raised adjusted earnings guidance to $46.30 to $46.95 per share from the prior outlook of $46.05 to $46.70.
MTD Zacks Rank & Stocks to Consider
Mettler-Toledo currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Medical sector include Agilent Technologies A, Agenus AGEN, and Doximity DOCS. While Agenus stock currently sports a Zacks Rank #1 (Strong Buy), Agilent Technologies and Doximity stock carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Agilent Technologies have lost 12.8% in the year-to-date period. Agilent Technologies is set to report the second quarter of fiscal 2026 results on May 27.
Agenus shares have gained 19.4% in the year-to-date period. Agenus is scheduled to report its first-quarter 2026 results on May 11.
Doximity shares have lost 41.3% in the year-to-date period. Doximity is set to report its fourth-quarter fiscal 2026 results on May 13.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Mettler-Toledo International, Inc. (MTD) : Free Stock Analysis Report
Doximity, Inc. (DOCS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Here's How Much a $1000 Investment in Keysight Made 10 Years Ago Would Be Worth Today
May 8, 2026
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Keysight (KEYS) ten years ago? It may not have been easy to hold on to KEYS for all that time, but if you did, how much would your investment be worth today?
Keysight's Business In-Depth
With that in mind, let's take a look at Keysight's main business drivers.
Based in Santa Rosa, CA, Keysight Technologies, Inc. is a provider of electronic design and test instrumentation systems. In 2013, Agilent Technologies announced that it will split into two independent companies. One of the companies was named Keysight Technologies, which became a fully independent electronic measurement company on Nov 1, 2014 and got listed on the New York Stock Exchange on Nov 3, 2014, with ticker symbol KEYS.
Keysight’s suite of connected car test solutions include Virtual Drive Test Toolset, which facilitates automakers to build virtual test routes in the lab by integrating network and channel emulation capabilities, and combining data captured in the field. Moreover, the company is evolving its expertise in software test automation capabilities.
Meanwhile, KeysightCare aids customers with end-to-end scalable support model solution loaded with robust test and measurement know-how to reduce time-to-market and enhance efficiency in a cost-effective manner.
Beginning first-quarter fiscal 2020, the company’s financial reporting comprises two segments — Electronic Industrial Solutions Group (EISG) and Communications Solutions Group (CSG). In the first-quarter fiscal 2026, the company generated revenues of $1.6 billion.
Under CSG segment (70.25% of revenues in the first-quarter fiscal 2026), the company offers radio frequency (RF) and microwave test instruments and allied software, and electronic design automation (EDA) software instruments, laser source products, optical amplifiers, and other software solutions.
The EISG segment (29.75% of revenues in the first-quarter fiscal 2026) offers test and measurement solutions across an array of electronic industrial end markets. It focuses on high-value applications in the automotive and energy industries and measurement solutions for consumer electronics, education, general electronics design and manufacturing, and semiconductor design and manufacturing. It also provides software and systems along with related services for use in the simulation, design, validation, manufacturing, installation and optimization of electronic equipment.
Story Continues
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Keysight a decade ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in May 2016 would be worth $13,666.67, or a gain of 1,266.67%, as of May 8, 2026, and this return excludes dividends but includes price increases.
The S&P 500 rose 256.67% and the price of gold increased 250.45% over the same time frame in comparison.
Analysts are forecasting more upside for KEYS too.
Keysight is benefiting from the growing proliferation of electronic content in vehicles, momentum in space and satellite applications, and the rising adoption of driver-assistance systems globally. The company's robust 5G product portfolio, ranging from Layer 1 to 7, enables telecom and semiconductor companies to accelerate their 5G initiatives. Management's focus on other emerging markets like the IoT and high-speed data centers bodes well for the top line. High demand for parametric wafer test solutions is supporting net sales in the ElSG segment. Strong focus on innovation is a positive. However, high dependency on contract manufacturing has made KEYS vulnerable to supply chain disruptions. The imposition of tariffs owing to the trade war between the United States and China is negatively impacting growth prospects.
The stock has jumped 9.95% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2026; the consensus estimate has moved up as well.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keysight Technologies Inc. (KEYS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Philips Q1 Earnings and Revenues Decrease Year over Year, Shares Up
May 7, 2026
Koninklijke Philips PHG reported first-quarter 2026 adjusted earnings of €0.23 per share, down 8.0% year over year. The company had reported adjusted earnings of €0.25 per share in the year-ago quarter.
Sales totaled €3.91 billion, down 4.7% on a reported basis. Comparable sales increased 4% year over year, which was driven by growth across all segments. The Diagnosis & Treatment segment recorded 2% growth, Connected Care recorded 3% growth and Personal Health showed 9% growth.
Further, Philips’ comparable order intake increased 6% year over year in the first quarter.
Geographically, comparable growth was led by Mature geographies, supported by strength in North America and Western Europe, while Growth geographies were flat on a comparable basis. Growth geographies showed flat comparable sales. Growth in the Diagnosis & Treatment and Personal Health segments was mainly offset by the segment Other and a slight decline in Connected Care. Comparable sales in Mature geographies grew 5% in the reported quarter, mainly driven by North America and Western Europe.
Koninklijke Philips N.V. Price, Consensus and EPS SurpriseKoninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
Philips’ stock gained 2.17% in pre-market trading.
PHG’s Segmental Update
Diagnosis & Treatment revenues declined 6% from the year-ago quarter to €1.85 billion. Comparable sales increased 2% year over year. High-single-digit growth in Image Guided Therapy was partly offset by a low-single-digit decline in Precision Diagnosis.
Connected Care revenues decreased 10.2% year over year to €1.06 billion. Comparable sales increased 3% year over year, mainly driven by mid-single-digit growth in Monitoring.
Personal Health revenues grew 0.9% year over year to €818 million. Comparable sales increased 9% year over year, driven by double-digit growth in Growth geographies and high-single-digit growth in Mature geographies.
Other segment sales amounted to €177 million, up 26.4% on a year-over-year basis.
PHG’s Operating Details
Gross margin contracted 10 basis points (bps) on a year-over-year basis to 45.1% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 4.5%, which expanded 60 bps on a year-over-year basis. Moreover, selling expenses decreased 70 bps year over year to 25.8%. Research & development expenses decreased 110 bps to 10.1%.
Restructuring, acquisition-related, and other items amounted to €61 million compared with €143 million a year ago.
Philips remains on track to deliver its three-year €1.5 billion productivity program, including €126 billion in savings in 2025.
Profitability was mixed by segment. Phillips adjusted EBITA — the company’s preferred measure of operational performance — decreased 0.3% year over year to €353 million. EBITA margin expanded 40 bps on a year-over-year basis to 9% in the reported quarter.
Diagnosis & Treatment recorded a 9.8% adjusted EBITA margin, up 30 basis points year over year. Connected Care’s adjusted EBITA margin declined 60 basis points to 2.9%, reflecting higher tariffs and cost inflation. Personal Health expanded adjusted EBITA margin by 60 basis points to 15.8%, supported by higher sales and productivity, partly offset by higher tariffs and increased advertising and promotions spend.
Story Continues
Philips Cash Flow Improves and Balance Sheet Stays Solid
As of March 31, 2025, Philips’ cash and cash equivalents were €2.59 billion compared with €2.79 billion as of Dec. 31, 2025.
Total debt was €8.10 billion compared with €8.08 billion as of Dec. 31, 2025.
Operating cash flow was €188 million versus €933 million outflow in the year-ago quarter, when results reflected a large Respironics-related settlement payment.
Free cash flow was positive €28 million against a €1.09 billion outflow a year earlier, reflecting improved earnings and working capital dynamics.
PHG Reiterates 2026 Outlook
PHG reiterated its full-year 2026 outlook, calling for 3%-4.5% comparable sales growth, an adjusted EBITA margin of 12.5%-13.0% and free cash flow of €1.3-€1.5 billion.
The company noted the outlook includes currently known tariff impacts within an uncertain macro environment and excludes potential tariff refunds and ongoing Philips Respironics-related proceedings.
PHG Zacks Rank & Stocks to Consider
Philips currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader Zacks Medical sector include Agilent Technologies A, Agenus AGEN, and Doximity DOCS. While Agenus stock currently sports a Zacks Rank #1 (Strong Buy), Agilent Technologies and Doximity stock carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Agilent Technologies have lost 13.5% in the year-to-date period. Agilent Technologies is set to report the second quarter of fiscal 2026 results on May 27.
Agenus shares have gained 23.8% in the year-to-date period. Agenus is scheduled to report its first-quarter 2026 results on May 11.
Doximity shares have lost 42% in the year-to-date period. Doximity is set to report its fourth-quarter fiscal 2026 results on May 13.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Doximity, Inc. (DOCS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
May 7, 2026
Apyx Medical (APYX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +54.55%. A quarter ago, it was expected that this medical device maker would post a loss of $0.06 per share when it actually produced a loss of $0.03, delivering a surprise of +50%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Apyx, which belongs to the Zacks Medical - Products industry, posted revenues of $12.49 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 6.23%. This compares to year-ago revenues of $9.43 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Apyx shares have lost about 16.6% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for Apyx?
While Apyx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Apyx was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.09 on $13.23 million in revenues for the coming quarter and -$0.34 on $58.07 million in revenues for the current fiscal year.
Story Continues
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Agilent Technologies (A), another stock in the same industry, has yet to report results for the quarter ended April 2026. The results are expected to be released on May 27.
This scientific instrument maker is expected to post quarterly earnings of $1.40 per share in its upcoming report, which represents a year-over-year change of +6.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Agilent Technologies' revenues are expected to be $1.8 billion, up 7.7% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apyx Medical Corporation (APYX) : Free Stock Analysis Report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Elemental Analysis Market Research and Global Forecasts Report 2025-2026 & 2030: Adoption Driven by Rising Demand in Emerging Economies and Expanding Global Water Quality Monitoring Mandates
May 7, 2026
Company Logo
The elemental analysis market is set to grow from USD 4.51 billion in 2025 to USD 6.48 billion by 2030, driven by regulatory pressures and industrial needs. The adoption of high-sensitivity technologies like ICP-OES is accelerating due to enhanced testing efficiency and accuracy. Key sectors like pharmaceuticals and biopharmaceuticals, facilitated by compliance regulations like ICH Q3D, dominate the market, alongside a burgeoning Asia-Pacific region. Major players, including Agilent Technologies and Thermo Fisher Scientific, are crucial stakeholders. Gain in-depth insights with our comprehensive report for strategic market opportunities and growth.
Elemental Analysis MarketElemental Analysis Market·GlobeNewswire Inc.
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Elemental Analysis Market by Type, Technique, End User - Global Forecasts to 2030" has been added to ResearchAndMarkets.com's offering.
The elemental analysis market is projected to experience significant growth, increasing from USD 4.51 billion in 2025 to USD 6.48 billion by 2030, at a CAGR of 7.4%.
This growth is driven by various regulatory, technological, and industrial factors. Increased awareness of health risks related to toxic metals like lead, arsenic, cadmium, and mercury has led to stricter regulations, demanding precise analytical methods from industries. Regulatory bodies such as the FDA, EPA, and REACH have set stringent testing standards, compelling industries to adopt reliable testing solutions.
Technological advancements, including ICP-OES, ICP-MS, and automated elemental analyzers, have enhanced testing accuracy and efficiency, facilitating regulatory compliance. The surge in environmental contamination due to rapid industrialization and urbanization in emerging economies has escalated the demand for routine elemental and heavy metal monitoring. Consumer demand for contaminant-free products in healthcare and personal care further boosts the adoption of advanced testing solutions, contributing to market expansion globally.
Leading companies involved include Agilent Technologies Inc., Thermo Fisher Scientific Inc., Bruker Corporation, PerkinElmer Inc., Shimadzu Corporation, SPECTRO Analytical Instruments GmbH, HORIBA Ltd., Analytik Jena AG, and others. These players are influential in shaping the market dynamics through cutting-edge technology and strategic initiatives.
ICP-OES holds the largest market share due to its superior performance in multi-element detection. With high sensitivity and precision, ICP-OES is ideal for applications in pharmaceuticals, environmental monitoring, and food safety. Its capability to handle elements at varying concentrations eliminates the need for multiple instruments, making it cost-effective and efficient. Regulatory approval of ICP-OES methods by pharmacopeias and environmental authorities supports its extensive adoption, ensuring its dominance in the elemental analysis market.
Story Continues
Pharmaceutical and biopharmaceutical companies lead the market owing to the critical need for monitoring elemental impurities in drug products. Regulatory guidelines such as ICH Q3D and USP 232 enforce limits on toxic metals in medications. Biopharmaceuticals require detailed elemental profiling to ensure safety and consistency. The complexity of drug formulations and outsourcing trends to CROs drive the demand for high-precision analytical instruments, reinforcing the sector's significant market share globally.
Asia-Pacific to exhibit the highest CAGR during the forecast period.
Although North America currently leads the market due to advanced regulatory frameworks and infrastructure, Asia-Pacific is set to grow rapidly. Factors such as industrialization, expanding pharmaceutical and biotechnology sectors, and increased healthcare investment drive this growth. Countries like China, India, and South Korea are enhancing their drug production capabilities and adopting advanced analytical instruments, which boosts the region's demand for testing solutions, thus positioning Asia-Pacific as a leading market segment.
Research Coverage and Benefits
Comprehensive study of the elemental analysis market based on brand, product type, procedure, end user, and region. Analysis of market growth factors, opportunities, and competitive landscape. Insights on promising markets and competitive assessments of major industry players. Discussion on key market drivers, restraints, opportunities, and challenges. In-depth analysis of product development, market diversification, and technological innovations.
Key Attributes:
Report Attribute Details No. of Pages 248 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $4.51 Billion Forecasted Market Value (USD) by 2030 $6.48 Billion Compound Annual Growth Rate 7.4% Regions Covered Global
Market Dynamics
Drivers
Stringent Global Environmental and Food-Safety Regulations Rising Public Health Burden and Contamination Events Expansion of Industrial and Resource-Extraction Activities Shift Toward Outsourced Testing and Accredited Labs
Restraints
High Capital and Operating Costs Shortage of Skilled Analytical Workforce Limited Laboratory Infrastructure in Emerging Economies
Opportunities
Rising Demand in Emerging Economies Expanding Global Water Quality Monitoring Mandates
Challenges
High Cost of Advanced Analytical Instruments Regulatory Complexity and Variation Sample Contamination and Accuracy Concerns
Company Profiles
Agilent Technologies, Inc. Thermo Fisher Scientific Inc. Bruker Perkinelmer Shimadzu Corporation Spectro Analytical Instruments GmbH Analytik Jena GmbH+Co. KG Horiba Elementar Analysensysteme GmbH Gbc Scientific Equipment Pty Ltd. (Gbcsci) Skyray Instruments, Inc. Malvern Panalytical Ltd. Rigaku Holdings Corporation Leco Corporation Advion, Inc. Teledyne Technologies Incorporated Hitachi, Ltd. Alpha Measurement Solutions LLC Buck Scientific Instruments LLC Jeol Ltd. Pg Instruments Labindia Instruments Pvt. Ltd. Aurora Biomed Inc. Beijing Beifen-Ruili Analytical Instrument (Group) Sciaps, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/nuzf5v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Elemental Analysis Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- Assessing Agilent Technologies (A) Valuation After FDA Approval Of PD L1 Assay For KEYTRUDA
May 6, 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Agilent Technologies (A) is back in focus after receiving U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx assay as a companion diagnostic for esophageal and gastroesophageal junction carcinoma patients eligible for KEYTRUDA.
See our latest analysis for Agilent Technologies.
The FDA approval comes as the stock shows a 4.77% 1 day share price return and a 12.59% 1 year total shareholder return, while weaker 90 day and year to date share price returns suggest momentum has recently been softer.
If you are looking beyond a single diagnostics stock, this could be a good moment to see what else is moving in healthcare focused AI, starting with 35 healthcare AI stocks.
With the stock up 12.59% over 1 year but showing weaker 90 day and year to date returns, and trading below the average analyst price target, you have to ask: is there still value here, or is the market already pricing in future growth?
Most Popular Narrative: 26.9% Undervalued
Agilent's most followed narrative places fair value at $160.69 versus a last close of $117.53, so the gap between price and story is sizeable.
Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.
Read the complete narrative.
Curious how a recurring revenue tilt, fatter margins, and a richer future earnings multiple combine into that fair value figure? The full narrative lays out the step by step earnings, revenue, and buyback assumptions behind it.
Result: Fair Value of $160.69 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to factor in risks like tariff related cost pressures and any prolonged funding weakness in academia and government budgets, as these could challenge this upside story.
Find out about the key risks to this Agilent Technologies narrative.
Another Angle On Valuation
The narrative points to a fair value of $160.69 and describes the stock as undervalued. However, the current P/E of 25.7x sits above the fair ratio of 21.7x, even though it is below peer averages of 32.3x and 36.5x. That mix of signals raises a simple question: how much valuation risk are you really comfortable with?
See what the numbers say about this price — find out in our valuation breakdown.
Story Continues
NYSE:A P/E Ratio as at May 2026
Next Steps
If the mix of upside and risk here seems finely balanced, it may be useful to review the data now and clarify your own stance by examining the 4 key rewards.
Looking for more investment ideas?
If this story has sharpened your thinking, do not stop here. The wider market is full of stocks with very different risk, income, and value profiles waiting to be assessed.
Target resilient cash generators by scanning companies in the solid balance sheet and fundamentals stocks screener (46 results) so you are focusing on businesses with fundamentals that can better handle tougher conditions. Hunt for mispriced opportunities using the 51 high quality undervalued stocks and see which stocks currently combine quality traits with prices that sit below their estimated worth. Build a stronger income stream by reviewing the 13 dividend fortresses and spot companies offering higher yields with an emphasis on stability and staying power.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include A.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
